I spent nearly fifty years living with severe headaches and occasional migraine attacks, starting in childhood. What began as an almost constant underlying headache, punctuated by severe episodes, followed me through my teenage years and into adulthood. Several of those migraine attacks were serious enough to require hospitalization. I moved through nearly every treatment available along the way — aspirin, then Excedrin, then prescription migraine medications, eventually narcotics, and at one point I was seriously considering Botox injections. One episode in particular lasted for days and simply would not respond to anything doctors tried. I’m not writing this article as an outside observer describing a condition I’ve read about. I lived inside it for most of my life.
This isn’t a small story. According to the World Health Organization, headache disorders affect roughly 40 percent of the global population, and migraine specifically ranks as the third-highest cause of disability-adjusted life years worldwide. That’s not a niche complaint. That’s tens of millions of people whose work, relationships, and daily functioning are shaped by a condition that, for decades, medicine had very little targeted to offer.
What follows is a grounded look at where things actually stand in 2026 — what the newer treatments do, what the evidence supports and doesn’t, and why the unglamorous basics (sleep, hydration, consistency) still carry real weight even in an era of targeted biologics. A few years ago, correcting a chronic electrolyte imbalance, particularly around magnesium, eliminated my own migraines and headaches almost entirely after decades of searching. That’s my experience, not a claim that it will work identically for everyone — migraine has too many different underlying mechanisms for any single fix to be universal. But it’s exactly why I take both sides of this seriously: the real, evidence-backed medical treatments available today, and the foundational, unglamorous factors that too often get dismissed as “just drink more water.” I’ve been failed by both extremes of that conversation at different points in my life.
In This Article
What Changed: The CGRP Era in Migraine Treatment
For most of modern medical history, migraine prevention relied on drugs developed for something else entirely — beta-blockers for blood pressure, certain antidepressants, and anti-seizure medications like topiramate and valproate. They can work, but they weren’t designed around migraine’s actual biology, and many people found the side effects hard to tolerate long enough to know if the drug was helping.
That began to change with the discovery that a molecule called calcitonin gene-related peptide, or CGRP, plays a central role in migraine pain. CGRP is released during an attack and contributes to the inflammation and pain signaling that produces migraine symptoms. Once researchers understood this mechanism, an entirely new category of migraine-specific drugs followed: monoclonal antibodies and small-molecule drugs called gepants, both built to interfere with CGRP activity rather than simply dulling pain in general.
The clearest sign of how far this field has moved is a March 2024 update from the American Headache Society’s position statement, which stated plainly that CGRP-targeting therapies are now a first-line option for migraine prevention — meaning patients no longer need to try and fail older medications first before a doctor can consider one of these newer drugs. That’s a meaningful shift in how migraine is treated, not just a new item added to the list.
Why Migraine Happens: The Short Version
Migraine involves the trigeminovascular system — a network of nerves connecting the face, head, and blood vessels surrounding the brain. During an attack, this system becomes activated, releasing CGRP and other signaling molecules that produce the inflammation, pain, and heightened sensitivity characteristic of migraine. This is also why migraine so often comes with more than head pain: nausea, light and sound sensitivity, and for some people, an aura of visual or sensory disturbances beforehand.
An important nuance here: things people describe as “triggers,” like food cravings, neck stiffness, or fatigue, are sometimes actually early symptoms of an attack that’s already beginning, called the prodrome phase, rather than the cause of it. That distinction matters, because it means some perceived triggers may be your body’s early warning system rather than something you did wrong.
Gepants and Monoclonal Antibodies: What’s the Difference
Both categories target CGRP, but they work differently and serve different purposes.
CGRP monoclonal antibodies — erenumab, fremanezumab, galcanezumab, and eptinezumab — are preventive medications given by injection or infusion, typically monthly or quarterly. They work by either blocking the CGRP receptor or binding to CGRP itself before it can act. These aren’t for stopping an attack in progress; they’re for reducing how often attacks happen in the first place.
Gepants — including rimegepant, atogepant, ubrogepant, and zavegepant — are small-molecule oral or nasal medications that block the CGRP receptor. Some, like ubrogepant and zavegepant, are used for acute treatment during an attack. Rimegepant is unusual in having both an acute and a preventive indication, and atogepant is approved specifically for prevention. One meaningful advantage of gepants over older acute medications like triptans is that they don’t cause the vasoconstriction that makes triptans unsuitable for people with certain cardiovascular conditions.
None of this means these drugs are interchangeable or that newer automatically means better for a given person. Dosing, approved ages, pregnancy considerations, and side-effect profiles all differ, which is exactly why this is a conversation to have with a neurologist or headache specialist rather than a decision to make from an article.
What the Evidence Actually Supports
The American Headache Society’s 2024 position statement didn’t arrive lightly. It was built on the argument that the cumulative evidence for CGRP-targeting therapies — in terms of efficacy, tolerability, and safety — now exceeds that of any established migraine preventive treatment, and that this evidence has held up consistently across individual drugs and been reinforced by real-world clinical experience, not just controlled trials.
That’s a strong claim, and it’s worth sitting with rather than treating it as marketing language. Randomized trials plus years of post-approval, real-world use is a meaningfully different evidence base than a single successful trial. It’s also worth noting that these are not universally life-changing for every patient — a meaningful share of people don’t respond fully, and “transformational for the field” is not the same claim as “guaranteed relief for you.”
Research continues to expand beyond CGRP as well. Scientists are now investigating a related molecule called PACAP, which appears to play a role in migraine through mechanisms that overlap with but aren’t identical to CGRP. Early trial results for an investigational PACAP-blocking antibody have shown reductions in monthly migraine days, though this remains experimental and years away from being an approved, available treatment. It’s an encouraging sign that the field isn’t finished evolving — but it’s not something to expect access to anytime soon.
What These Treatments Don’t Do
This is where balance matters most, because it’s easy for genuinely good medical news to get inflated into something it isn’t.
- CGRP-targeting therapies do not cure migraine. They reduce frequency and severity for many patients; they don’t eliminate the underlying neurological predisposition.
- They are not risk-free. Ongoing real-world safety monitoring has identified emerging concerns, including the potential for these drugs to cause or worsen hypertension and Raynaud’s phenomenon — significant enough that the FDA updated safety labeling for CGRP monoclonal antibodies and gepants in March 2025 to reflect this.
- They don’t work for everyone. Some patients see little to no benefit, and switching between agents or trying a different mechanism entirely is sometimes necessary.
- They are not a substitute for an accurate diagnosis. Not every recurring headache is migraine, and starting a CGRP-targeting therapy without ruling out other causes of headache can delay appropriate care for something else entirely.
None of this is a reason for skepticism toward the treatments themselves. It’s a reason to engage with them the way you should engage with any medical treatment — as a real option with real tradeoffs, evaluated with a clinician who knows your full history, not as a miracle cure or a scheme to be suspicious of.
Who May Benefit, and Who Should Be Cautious
People who may be reasonable candidates for a conversation about CGRP-targeting therapy include those with frequent or disabling migraine attacks, those who haven’t tolerated or responded well to older preventive medications, and those for whom triptans are contraindicated due to cardiovascular risk factors. The 2024 position statement update specifically removed the requirement to fail older drugs first, so “I haven’t tried the old options yet” is no longer automatically a barrier to this conversation.
People who should approach these treatments with extra caution and thorough medical oversight include those with existing hypertension, Raynaud’s phenomenon or similar vascular sensitivity, those who are pregnant or planning pregnancy, and anyone with significant kidney or liver impairment relevant to a specific agent’s labeling. This is also true more broadly for anyone managing a complex neurological picture — for instance, if seizures and migraine coexist, medication interactions and shared neurological triggers deserve careful coordination between specialists rather than treating each condition in isolation.
Common Myths About Migraine and Its Treatment
Myth: Migraine is just a bad headache. Migraine is a distinct neurological disease involving a specific cascade of nerve activation and inflammatory signaling. The pain is one symptom among several, and for many patients, it isn’t even the most disabling one.
Myth: If a trigger causes your migraine, avoiding it will cure you. Trigger identification is genuinely useful for reducing attack frequency, but migraine is a underlying neurological predisposition. Perfect trigger avoidance rarely eliminates attacks entirely, and chasing an impossible standard of avoidance can become its own source of stress, which is itself a common trigger.
Myth: Newer, more expensive treatments are automatically better than older ones. Older preventive medications remain reasonable, effective first-line choices for many people. The point of the 2024 position statement update wasn’t that older drugs are obsolete — it was that patients shouldn’t be required to fail them first before newer options can be discussed.
Myth: You just have to push through it. Undertreated migraine, including reliance on over-the-counter pain relievers used too many days per month, can itself cause a separate problem called medication-overuse headache. Pushing through isn’t a neutral choice; it can actively make the underlying pattern harder to treat.
The Foundations That Still Matter
Even with genuinely transformative drugs now available, the WHO’s guidance on migraine still emphasizes the unglamorous basics: regular sleep and exercise schedules, staying hydrated, moderating or eliminating alcohol, and keeping a headache diary to identify your own patterns. This isn’t a consolation prize for people who can’t access newer treatments — it’s foundational care that makes any treatment, old or new, work better.
Sleep deserves particular attention. Both sleep deprivation and irregular sleep timing are well-documented migraine triggers, and the relationship runs in both directions — poor sleep can trigger attacks, and migraine attacks can disrupt sleep, creating a cycle that’s hard to break without deliberately addressing the sleep side first.
I’ll admit this somewhat sheepishly: it wasn’t until much later in my life that I made the connection between proper nutrition, the right electrolyte balance, sleep, and how much they were actually driving my headache pattern. For decades I was focused entirely on the next medication, the next specialist, the next thing to try — and it never occurred to me that something as basic as an electrolyte imbalance could be sitting underneath all of it. Recognizing that connection, late as it came, is what finally brought my headaches under control.
Magnesium is the piece that changed everything for me personally. After decades of cycling through medications, correcting a chronic electrolyte imbalance — with magnesium at the center of it — was what finally brought my own migraines and near-constant headaches to an end. Deficiency has a well-documented connection to migraine frequency, along with anxiety and poor sleep more broadly, and it’s exactly the kind of foundational factor that’s easy to overlook when you’re focused on finding the next medication to try. I’ve written more fully about magnesium’s role in this deeper look at magnesium deficiency, seizure threshold, and its overlap with migraine and sleep if you want to go further on that specific piece.
Hydration, consistent caffeine intake rather than fluctuating amounts, and regular meal timing round out the foundational list. None of these will replace an appropriate medical treatment plan for someone with frequent, disabling migraine — but they consistently show up as legitimate, evidence-supported contributors to how often attacks occur and how severe they are.
🛒 Shop This Category
If magnesium, hydration, or sleep support are part of how you’re addressing migraine foundations, here’s where I source the electrolyte and mineral products I actually use.
A Faith Note on Living With an Invisible Condition
Migraine, like many neurological conditions, is invisible to everyone but the person carrying it. I spent decades where no one around me could see the pain I was in, and I know how isolating that is. Scripture doesn’t promise that faithful people are spared from this kind of suffering, but it does speak directly to enduring what isn’t visible to others. “For we walk by faith, not by sight,” Paul writes in 2 Corinthians 5:7 (NASB 1995) — a verse about far more than migraine, but one that carried real weight for me during the years I couldn’t find an answer. Wisdom, in this context, looked like refusing to give up on finding real relief, while also extending myself the patience an invisible illness demands.
Frequently Asked Questions
Do I need to fail older medications before trying a CGRP-targeting therapy?
Not according to current guidance. The American Headache Society’s 2024 position statement update specifically removed the requirement to try and fail traditional preventive medications first. Whether your insurance follows that guidance is a separate, and unfortunately common, complication.
Are CGRP drugs safe long-term?
They’ve been remarkably safe so far, but they haven’t been on the market as long as older drug classes, and real-world surveillance has identified some emerging concerns, including hypertension and Raynaud’s phenomenon risk significant enough to prompt an FDA safety labeling update in March 2025. Long-term use should include ongoing monitoring with your prescribing physician.
What’s the difference between a migraine and a bad headache?
Migraine is a distinct neurological disease with a specific symptom pattern that typically includes moderate-to-severe pain, sensitivity to light and sound, and often nausea, sometimes preceded by an aura. A tension headache, by contrast, is generally described as pressure or tightness without those accompanying features. A proper diagnosis from a healthcare provider matters more than self-identifying based on severity alone.
Can lifestyle changes alone manage migraine?
For some people with mild, infrequent attacks, foundational habits like consistent sleep, hydration, and trigger awareness may be enough. For others with frequent or disabling migraine, lifestyle measures are an important complement to medical treatment rather than a replacement for it.
Where This Leaves You
Migraine treatment has genuinely changed for the better over the past several years, and that’s worth taking seriously if you’ve been managing this condition with tools that felt inadequate. At the same time, none of these advances erase the need for an accurate diagnosis, an honest conversation with a qualified neurologist about your specific risk factors, and the unglamorous daily habits that continue to matter regardless of what’s in your medicine cabinet.
If you take one thing from this: don’t let “it’s just a headache” — from others or from your own internal voice — talk you out of pursuing real treatment for a real neurological disease. The tools available today are genuinely better than they were even a decade ago. That’s worth acting on.
Sources & Further Reading
- World Health Organization — Migraine and Other Headache Disorders Fact Sheet (2025)
- Charles AC, et al. — Calcitonin Gene-Related Peptide-Targeting Therapies Are a First-Line Option for the Prevention of Migraine: An American Headache Society Position Statement Update. Headache, 2024.
- Russo AF, Kaiser EA — CGRP and Migraine: Real-World Insights and Future Therapeutic Directions. Annual Review of Medicine, 2026.
- Ashina M, et al. — A Monoclonal Antibody to PACAP for Migraine Prevention. New England Journal of Medicine, 2024.
- NVA — Magnesium: The Invisible Deficiency Behind Anxiety, Migraines, and Poor Sleep
This article is for educational purposes and reflects publicly available research as of September 2026. It is not a substitute for personalized medical advice. If you’re experiencing frequent or worsening headaches, please consult a neurologist or headache specialist for an accurate diagnosis and treatment plan.